Скачать или смотреть 2023 Boston CannabizMD Cannabis Science + Policy Forum: Federal Policy + Regulations

A federal-state divide exists in cannabis policy while it remains classified as a Schedule I drug by the DEA. Healthcare providers, researchers, and medical cannabis industry professionals are uniquely challenged by the navigation of federal regulations, public policy, and the impact on public health.

Moderated by Karen Jaynes, MS, roundtable members discussed the complex federal regulatory landscape along with likely next steps for federal cannabis drug policy reform, the impact of the 2022 Medical Marijuana
and Cannabidiol Research Expansion Act, and the 2023 Farm Bill.

Roundtable Members:
Kristine Blackwood: Healthcare Policy Counsel, Arnold & Porter

Bryant Godfrey: FDA/Life Sciences Attorney, Foley Hoag LLP

Jay Wexler: Professor and Author, Boston University Law School